NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Himuka AM Pharma Corp.

Himuka AM Pharma Corp.

Private
MiyazakiHealthcare & Life Scienceshttps://www.himuka-am.com/

Last Round

Series B

Jan 14, 2022

Total Funding Raised

$10.67M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Himuka AM Pharma Corp. is a clinical-stage biopharmaceutical company that develops drug candidates based on derivatives of the bioactive peptide adrenomedullin to address unmet medical needs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoverypeptide therapeuticsadrenomedullinclinical-stage biotechdrug licensinginflammatory bowel diseaseIBDtissue regenerationangiogenesisbiotech startupdrug pipelineCADASILbiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Himuka AM Pharma Corp. Comps

Public and private peers based on sector, stage, and business model.

Himuka AM Pharma Corp. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Himuka AM Pharma Corp. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 14, 2022
Series AJun 19, 2018

Himuka AM Pharma Corp. Investors

Notable investors and investment history

Himuka AM Pharma Corp. investors
InvestorRounds
Keio Innovation InitiativeSeries A
Nanto BankSeries B
日本ベンチャーキャピタル株式会社Series A
Miyazaki Taiyo CapitalSeries B, Series A
Venture Labo InvestmentSeries B
Axil Capital PartnersSeries A
QB CapitalSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 24, 2026

    Monthly visitors grew 40% MoM.

Himuka AM Pharma Corp. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Himuka AM Pharma Corp. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Himuka AM Pharma Corp.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersMiyazaki
Employee Range1
Year Founded2017
Last FundingJan 14, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.